Bitcoin halving
What does that mean?
$2.78T
Total marketcap
$107.28B
Total volume
BTC 49.61%     ETH 15.34%
Dominance

AstraZeneca PLC AZN.BA Stock

37027 ARS {{ price }} 1.366075% {{change_pct}}%
COUNTRY
Argentina
Market Cap
235.86T ARS
LOW - HIGH [24H]
36750 - 37481 ARS
VOLUME [24H]
176 ARS
{{ volume }}
P/E Ratio
697.70
Earnings per share
53.07 ARS

AstraZeneca PLC Price Chart

AstraZeneca PLC AZN.BA Financial and Trading Overview

AstraZeneca PLC stock price 37027 ARS
Previous Close 31577 ARS
Open 32467.5 ARS
Bid 32000 ARS x N/A
Ask 32689 ARS x N/A
Day's Range 32121.5 - 33333 ARS
52 Week Range 214.5 - 33333 ARS
Volume 8.74K ARS
Avg. Volume 0 ARS
Market Cap 204.94T ARS
Beta (5Y Monthly) 0.162
PE Ratio (TTM) 606.23706
EPS (TTM) 53.07 ARS
Forward Dividend & Yield 10.83 (5.05%)
Ex-Dividend Date August 10, 2023
1y Target Est N/A

AZN.BA Valuation Measures

Enterprise Value 49.96T ARS
Trailing P/E 606.23706
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4607.0127
Price/Book (mrq) 1333.6511
Enterprise Value/Revenue 1122.966
Enterprise Value/EBITDA 2836.749

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.162
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 33333 ARS
52 Week Low 214.5 ARS
50-Day Moving Average 214.5 ARS
200-Day Moving Average 214.5 ARS

AZN.BA Share Statistics

Avg. Volume (3 month) 0 ARS
Avg. Daily Volume (10-Days) 0 ARS
Shares Outstanding 1.55B
Float 1.55B
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.9
Trailing Annual Dividend Yield 0.0091%
5 Year Average Dividend Yield N/A
Payout Ratio 0.22950001
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) June 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 13.85%
Operating Margin (ttm) 22.79%
Gross Margin 86.96%
EBITDA Margin 39.58%

Management Effectiveness

Return on Assets (ttm) 8.32%
Return on Equity (ttm) 16.81%

Income Statement

Revenue (ttm) 44.49B ARS
Revenue Per Share (ttm) 2.38 ARS
Quarterly Revenue Growth (yoy) 6.00%
Gross Profit (ttm) 35.73B ARS
EBITDA 17.61B ARS
Net Income Avi to Common (ttm) 6.16B ARS
Diluted EPS (ttm) 53.07
Quarterly Earnings Growth (yoy) 405.00%

Balance Sheet

Total Cash (mrq) 5.81B ARS
Total Cash Per Share (mrq) 3.75 ARS
Total Debt (mrq) 30.79B ARS
Total Debt/Equity (mrq) 82.3 ARS
Current Ratio (mrq) 0.866
Book Value Per Share (mrq) 24.124

Cash Flow Statement

Operating Cash Flow (ttm) 10.18B ARS
Levered Free Cash Flow (ttm) 10.94B ARS

Profile of AstraZeneca PLC

Country Argentina
State N/A
City Cambridge
Address 1 Francis Crick Avenue
ZIP CB2 0AA
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 83500

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current AZN.BA stock price?

AstraZeneca PLC AZN.BA stock price today per share is 37027 ARS.

How to purchase AstraZeneca PLC stock?

You can buy AZN.BA shares on the Buenos Aires exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is AZN.BA.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers-General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 6.37B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is 697.70120000 now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is 53.07 ARS over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.